Pfizer Inc. (NYSE: PFE, /ˈfaɪzər/) is an American multinational pharmaceutical corporation headquartered in New York City was founded in 1849, based in New York City and was listed on New York Stock Exchange. It is one of the world's largest pharmaceutical companies. It is listed on the New York Stock Exchange, and its shares have been a component of the Dow Jones Industrial Average since 2004. Pfizer ranked No. 57 on the 2018 Fortune 500 list of the largest United States corporations by total revenue.

Senju Pharmaceutical Beijing Co. Ltd., part of Senju Pharmaceutical Co., Ltd., is a company headquartered in Beijing, China, that manufactures and distributes pharmaceuticals.

AxeroVision, Inc., part of Chuangsheng Qiao Kang Pharmaceutical Co. Ltd., is a company headquartered in Carlsbad, CA. The firm develops therapies for the treatment of Dry Eye Disease (DED) and other ophthalmic inflammatory problems. It was founded in 2016 by Achim Krauss, who has been the CEO since the company founding. On July 28, 2023 Chuangsheng Qiao Kang Pharmaceutical Co. Ltd. acquired AxeroVision, Inc.

Dermavant Sciences GmbH, a subsidiary of Roivant Sciences Ltd., is a company headquartered in Basel, Switzerland. The firm develops and commercializes therapeutics in medical dermatology.

Eisai R&D Management Co., Ltd., a subsidiary of Eisai Co., Ltd., is a company headquartered in Bunkyo, Japan. The firm engages in research and development of pharmaceuticals.

Pharmaleads aims to provide patients suffering from severe chronic and acute pain with improved pain relief without the side effects associated with other classes of analgesics. Based on years of experience in the design of highly potent and specific inhibitors of enkephalinases, Pharmaleads has developed a new class of analgesics called DENKIs (Dual Enkephalinases inhibitors). These small molecules are able to provide patients with local and sustainable pain relief. Pharmaleads’ DENKIs are first-in-class drugs with a novel mechanism of action tackling pain by using endogenous enkephalins, natural peptides that specifically bind to pain-related opioid receptors to naturally modulate pain without the side effects observed with exogenous opioid drugs that also bind to other opioids receptors, not involved in pain control, triggering multiple side effects. Pharmaleads believes its products can change the lives of the many patients who are in need of improved treatment options for their chronic and/or acute pain, and could offer healthcare providers with an improved pain management option that helps address the opioid epidemic.

Boehringer Ingelheim International GmbH manufactures pharmaceutical prodcuts. It offers human and animal health products. The company was founded by Albert Boehringer in 1885 and is headquartered in Ingelheim, Germany.

Sichuan Jiuzhang Biotechnology Co., Ltd., established on 1999-04-27, Business scope includes drug research and development;chemical reagent(Free of Hazardous Chemicals)Research,Sales;Polymer Materials,biomaterials(Except for those prohibited by national laws and regulations and with special provisions)Research,Production,Sales;Sales:Chemical Products(Free of Hazardous Chemicals);Import and export,Technology Import and Export(National law,Except where prohibited by administrative regulations;law,Projects restricted by administrative regulations can only be operated after obtaining a license;The industrial industry involved in production establishes another branch or chooses another business site for operation);Sales of Jiuzhang Lutai Chewable Tablets(Operate within the validity period with the license).(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments).

Ocugen is a clinical-stage biopharmaceutical company focused on discoverinOcugen Inc is a clinical-stage biopharmaceutical business focused on discovering, developing, and commercializing gene treatments to cure blinding illnesses, as well as developing a COVID-19 vaccine to save lives. The biologic product candidate aims to provide better therapy to patients with underserved diseases such as wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy using the breakthrough modifier gene therapy platform.

Pfizer Ltd. is a biopharmaceutical company that develops and provides medicines, vaccines, and consumer healthcare products. Its products include prescription and counterfeit medicines, and over-the-counter products. The company was founded in 1952 and is headquartered in Tadworth, the United Kingdom.

4D Pharma Research Ltd., a subsidiary of 4D Pharma Plc, is a company headquartered in Aberdeen, UK, that engages in research and experimental development on biotechnology.

Part of Bausch Health Cos., Inc., Bausch & Lomb Pharma Holdings Corp. is an American company that manufactures and markets pharmaceutical products.

Xigen SA develops intracellular peptide therapeutics for the treatment of stroke, myocardial infarction and cancer. It focuses on the acute or short-term treatment of major debilitating pathologies that underly unmet medical needs plaguing humanity. The company was founded in 2002 and is headquartered in Epalinges, Switzerland.

Virginia Tech Intellectual Properties, Inc. handles, protects and licenses technologies developed by the faculty, staff and students. It facilitates the licensing of technology to companies, encourages new faculty startup ventures, works with publishers and distributors of software, and supports the transfer of research and knowledge to other universities, research institutes and companies. The company was founded in 1985 and is headquartered in Blacksburg, VA.

Santen Pharmaceutical Co., Ltd engages in the manufacture and sale of pharmaceutical products and medical devices. It operates through the following segments: Pharmaceuticals and Others. The Pharmaceuticals segment includes prescription ophthalmic drugs, anti-rheumatic pharmaceuticals, and over-the-counter products. The Others segment offers medical equipment and devices. The company was founded by Kenkichi Tagushi in 1890 and is headquartered in Osaka, Japan.

Hefei Huawei Pharmaceutical Co., Ltd., established on 1995-01-28, The business scope includes granules,Capsules,tablet,Solution(Including external use),Eye drop production(Operate within the validity period of the drug production license);Health food production and sales;anti-(suppress)Bacterial preparation(liquid,gel)(purify),liquid disinfectant(purify)production and sales of;one type,Production and sales of Class II medical equipment;Biotechnology,drug development,Technology Development and Transfer,Technical Consulting and Services;Business Management Consulting;Market Consulting,Promotion service;Meeting,Exhibition service.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Incyte is a drug discovery and development company which hopes to build a proprietary product pipeline of novel small molecule drugs. Incyte's product pipeline is currently focused on oncology and inflammation and includes compounds in various stages of development. Through partnerships with [Novartis](/organization/novartis), [Eli Lilly](/organization/eli-lilly), and [Pfizer](/organization/pfizer), Incyte intends to promote the clinical development and global commercialization of several of their compounds.